This site is intended for healthcare professionals

FDA accepts filing of palovarotene for fibrodysplasia ossificans progressiva.- Ipsen

Read time: 1 mins
Last updated:28th Jun 2021
Published:29th May 2021
Ipsen announced that its New Drug Application (NDA) for palovarotene, an oral, investigational, selective RARy agonist for the prevention of heterotopic ossification (new bone formation) as a potential treatment option for people living with the progressive disabling and ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP), has been accepted by the U.S. Food and Drug Administration (FDA).
Condition: Fibrodysplasia Ossificans Progressiva
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest